Novo Nordisk has acquired the global rights to United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn.

Novo Nordisk and The United Laboratories (TUL) have entered into an exclusive license agreement for UBT251, a triple receptor agonist targeting GLP-1, GIP, and glucagon, currently in early-stage ...

Novo Nordisk has decided that it wants its own triple agonist, and is willing to hand over $200 million upfront to United Laboratories’ subsidiary United Biotechnology. In return for the global ...

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn as the Wegovy (semalgutide) developer ...

Danish biopharma powerhouse Novo Nordisk is taking another bold move ... Novo picked up the new triple agonist, UBT251, from China-based United Biotechnology. The candidate, which is still in ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO ... Researchers believe the GLP-1 agonist market could triple over the next decade to over $150 billion. Where to invest $1,000 right now?

today announced that Novo Nordisk and TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology), have entered into an exclusive license agreement for UBT251, a ...

today announced that Novo Nordisk and TUL's wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology), have entered into an exclusive license agreement for UBT251, a ...

Novo Nordisk has said will be gaining exclusive worldwide rights to United Laboratories International’s investigational triple receptor agonist in a deal worth up to $2bn. The candidate, UBT251, is a ...

a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases. “Novo Nordisk is dedicated ...